Michael Krupp, Ph.D
Dr. Krupp is a Business and Technology Adviser the von Liebig Center for Entrepreneurism and Technology advancement at the UCSD Jacobs School of Engineering focused on the Life Sciences area. In addition, He also is currently the CEO of two startup companies, Neurgain Technologies and Xfibra, LLC, that are based on UC San Diego technologies. Dr. Krupp is a member of the Board of the CONNECT Foundation.
Previously Dr. Krupp was Sr. V.P. of Business Development and Chief Business Officer of Chugai Pharma USA, LLC (CPUSA) in San Diego. Dr. Krupp was responsible for identifying and acquiring products and technology to complement and expand CPUSA’s project pipeline. He lead the market research and strategic marketing efforts for Chugai drug candidates outside of Japan including the recently approved anti-IL-6 receptor antibody, Actemira, a novel agent for the treatment of rheumatoid arthritis. He was also responsible for general business operations. Prior to Chugai, Dr. Krupp served as Director, Licensing and Development, at Pfizer, Inc. He started his industry career in Pfizer Central Research in the areas of Diabetes drug discovery and General Pharmacology.
Dr. Krupp received his B.S. in Chemistry from Hobart College and his Ph.D. in Biochemistry from the University of Rochester, School of Medicine. He completed his Postdoctoral Research at The Johns Hopkins University School of Medicine.